BMO Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)

July 23, 2024 8:57 AM EDT Send to a Friend
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $67.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login